Literature DB >> 21416246

The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists.

Ponni V Perumalswami1, Thomas D Schiano.   

Abstract

BACKGROUND: Cirrhosis and chronic liver disease carry appreciable morbidity and mortality. Cirrhotic patients frequently require hospitalization and their care is both extremely complex and labor-intensive. AIM: We seek to provide a review for gastroenterologists, hepatologists, internists, and hospitalists on the approach to care in patients hospitalized for complications related to end-stage liver disease.
METHODS: The Mount Sinai Medical Center's inpatient liver service has developed an integrated team approach for cirrhotic patients and throughout the years has educated fellows-in-training and medical house staff on both the treatment principles and "pearls" in managing the hospitalized cirrhotic patient. We reviewed the literature and provide recommendations on the management of complications of end-stage liver disease. Additionally, we provide a review of the protocols used at our institution in the care for cirrhotic patients.
RESULTS: Major complications of advanced liver disease include infection, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, portal hypertension, variceal hemorrhage, hepatorenal syndrome, and hepatocellular carcinoma. Management of these complications involves selecting the appropriate diagnostic studies and prompt administration of therapy.
CONCLUSIONS: There are many complications of cirrhosis. Management of these complications can be complex and are targeted at stabilizing the patient's clinical condition. Liver transplantation remains the only definitive treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21416246     DOI: 10.1007/s10620-011-1619-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  112 in total

1.  Deaths: final data for 2002.

Authors:  Kenneth D Kochanek; Sherry L Murphy; Robert N Anderson; Chester Scott
Journal:  Natl Vital Stat Rep       Date:  2004-10-12

Review 2.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

3.  Antibiotic prophylaxis for GI endoscopy.

Authors:  Subhas Banerjee; Bo Shen; Todd H Baron; Douglas B Nelson; Michelle A Anderson; Brooks D Cash; Jason A Dominitz; S Ian Gan; M Edwyn Harrison; Steven O Ikenberry; Sanjay B Jagannath; David Lichtenstein; Robert D Fanelli; Ken Lee; Trina van Guilder; Leslie E Stewart
Journal:  Gastrointest Endosc       Date:  2008-03-28       Impact factor: 9.427

4.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

Authors:  Alexander L Gerbes; Veit Gülberg; Pere Ginès; Guy Decaux; Peter Gross; Hassan Gandjini; Jacques Djian
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

Review 5.  Hepatic hydrothorax: pathogenesis, diagnosis, and management.

Authors:  K N Lazaridis; J W Frank; M J Krowka; P S Kamath
Journal:  Am J Med       Date:  1999-09       Impact factor: 4.965

6.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.

Authors:  Martin Rössle; Alexander L Gerbes
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

7.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

Review 8.  Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology.

Authors:  Stanley Goldfarb; Peter A McCullough; John McDermott; Spencer B Gay
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

9.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.

Authors:  Christophe Bureau; Juan Carlos Garcia Pagan; Gilles Pomier Layrargues; Sophie Metivier; Pablo Bellot; Pierre Perreault; Philippe Otal; Juan-G Abraldes; Jean Marie Peron; Hervé Rousseau; Jaume Bosch; Jean Pierre Vinel
Journal:  Liver Int       Date:  2007-08       Impact factor: 5.828

10.  Neomycin reduces the intestinal production of ammonia from glutamine.

Authors:  R A Hawkins; J Jessy; A M Mans; A Chedid; M R DeJoseph
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

View more
  4 in total

1.  Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis.

Authors:  A M Walling; S C Ahluwalia; N S Wenger; M Booth; C P Roth; K Lorenz; F Kanwal; S Dy; S M Asch
Journal:  Dig Dis Sci       Date:  2016-11-01       Impact factor: 3.487

2.  Improving survival in decompensated cirrhosis.

Authors:  Amar Nath Mukerji; Vishal Patel; Ashokkumar Jain
Journal:  Int J Hepatol       Date:  2012-07-02

3.  The role of serum procalcitonin levels in predicting ascitic fluid infection in hospitalized cirrhotic and non-cirrhotic patients.

Authors:  Yesim Cekin; Ayhan Hilmi Cekin; Adil Duman; Ustun Yilmaz; Bayram Yesil; Basak Oguz Yolcular
Journal:  Int J Med Sci       Date:  2013-08-20       Impact factor: 3.738

4.  Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.

Authors:  Isao Sakaida; Shuji Terai; Koji Nakajima; Yoshiyuki Shibasaki; Sayaka Tachikawa; Hidetsugu Tsubouchi
Journal:  J Gastroenterol       Date:  2016-07-05       Impact factor: 7.527

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.